Agustín Melián

Agustín joined Forma in July 2022 and has more than 20 years of experience in developing patient-centric, rare and orphan disease therapies across multiple therapeutics areas, multiple modalities, and all phases of development. Agustín is the head of research and development, a new position created for Forma’s next phase of growth across R&D, late-stage global development and commercialization. Prior to joining Forma, Agustín served as the first chief medical officer at AlloVir, Inc., where he played a foundational role building its development organization, taking the company through its initial public offering and advancing programs through early and late-stage development. Agustín was also SVP and head of global medical sciences at Alexion Pharmaceuticals, Inc., where he applied innovative approaches and techniques to R&D and advanced the programs that quadrupled the number of products on the market during his tenure at the company. Earlier in his career, Agustín served for more than 13 years at Merck & Co, Inc. in various roles of increasing responsibility, including as global medical organization leader and head of Japanese clinical development. Here, he led the cross-functional R&D medical staff outside of the U.S. as well as in Japan. He oversaw clinical trial execution in approximately 40 countries, including in Latin America, Eastern Europe, the Middle East, Africa and Asia. Agustín earned a Bachelor of Science in molecular biology and biophysics along with an M.D. from Yale University. He completed his internship, residency and fellowship at Brigham and Women’s Hospital in Boston.